Otonomy, Inc. (“The Company” or “Otonomy”) is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The Company’s primary focus is currently on the advancement of three programs in their broad pipeline: OTO-313 in a Phase 2 trial for tinnitus; OTO-413 in an expansion Phase 1/2 trial for hearing loss; and OTO-825, a gene therapy for congenital hearing loss, in IND-enabling activities. Additionally, Otonomy is conducting preclinical development for OTO-510 in otoprotection and OTO-6XX for severe hearing loss.